Literature DB >> 15686627

HGF/SF-Met signaling in tumor progression.

Chong Feng Gao1, George F Vande Woude.   

Abstract

Tumor progression is a multi-step process that requires a sequential selection of specific malignant phenotypes. Met activation may induce different phenotypes depending on tumor stage: inducing proliferation and angiogenesis in primary tumors, stimulating motility to form micrometastases, and regaining the proliferation phenotype to form overt metastases. To study how HGF/SF-induced proliferative phenotypes switch to the invasive phenotype is important for understanding the mechanism of tumor progression and will provide an attractive target for cancer intervention and therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686627     DOI: 10.1038/sj.cr.7290264

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  64 in total

Review 1.  Overcoming resistance to antiangiogenic therapies.

Authors:  Sabine Tejpar; Hans Prenen; Massimiliano Mazzone
Journal:  Oncologist       Date:  2012-07-06

Review 2.  Gene therapy for radioprotection.

Authors:  W H Everett; D T Curiel
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

3.  Breast cancer associated fibroblasts promote MCF-7 invasion in vitro by secretion of HGF.

Authors:  Pingbo Chen; Qingqing Mo; Beibei Wang; Danhui Weng; Peng Wu; Gang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

4.  Analysis of receptor tyrosine kinase internalization using flow cytometry.

Authors:  Ning Li; Kristen S Hill; Lisa A Elferink
Journal:  Methods Mol Biol       Date:  2008

5.  Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.

Authors:  Pankaj K Singh; Michelle E Behrens; John P Eggers; Ronald L Cerny; Jennifer M Bailey; Kandavel Shanmugam; Sandra J Gendler; Eric P Bennett; Michael A Hollingsworth
Journal:  J Biol Chem       Date:  2008-07-14       Impact factor: 5.157

6.  Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Authors:  Murugabaskar Balan; Eduardo Mier y Teran; Ana Maria Waaga-Gasser; Martin Gasser; Toni K Choueiri; Gordon Freeman; Soumitro Pal
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

7.  LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.

Authors:  David L Shattuck; Jamie K Miller; Melanie Laederich; Melanie Funes; Heidi Petersen; Kermit L Carraway; Colleen Sweeney
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

8.  Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Authors:  Andreas Varkaris; Sanchaika Gaur; Nila U Parikh; Jian H Song; Farshid Dayyani; Jung-Kang Jin; Christopher J Logothetis; Gary E Gallick
Journal:  Int J Cancer       Date:  2013-04-17       Impact factor: 7.396

9.  Hepatocyte-specific c-Met deletion disrupts redox homeostasis and sensitizes to Fas-mediated apoptosis.

Authors:  Luis E Gómez-Quiroz; Valentina M Factor; Pal Kaposi-Novak; Cedric Coulouarn; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  J Biol Chem       Date:  2008-03-18       Impact factor: 5.157

10.  Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma.

Authors:  Gregory A Watson; Pierre E Queiroz de Oliveira; Michael T Stang; Michaele J Armstrong; William E Gooding; Shih-Fan Kuan; John H Yim; Steven J Hughes
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.